Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-07-19
1995-04-25
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142325, 5142328, 514255, 514259, A61K 31505
Patent
active
054099269
ABSTRACT:
Novel disubstituted 6-aminoquinazolinones of the Formula ##STR1## are useful as angiotensin-II receptor (subtype 2) antagonists (AT.sub.2 antagonists) alone or in combination with heparin, and can act to suppress the vascular stenosis which commonly occurs during the development of atherosclerosis and the restenosis following arterial angioplasty, stent placement, bypass surgery, heart transplantation or endarterectomy.
REFERENCES:
patent: 5162325 (1992-11-01), Chakravarty et al.
patent: 5238942 (1993-08-01), Chakravarty et al.
patent: 5240928 (1993-08-01), Allen et al.
patent: 5246943 (1993-09-01), Blankley et al.
patent: 5276048 (1994-01-01), Hodges et al.
Hypertension, vol. 20, p. 737 (1992).
J. Pharmacology and Exp. Therapeutics, vol. 225, No. 3 (1983) pp. 584-592, J. R. Shepard et al.
deLaszlo Stephen E.
Fujita Tsuneo
Johnson Robert G.
Reilly Christopher F.
Cintins Marianne M.
Jarvis William R. A.
Merck & Co. , Inc.
LandOfFree
AT-2 antagonist inhibition of vascular restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with AT-2 antagonist inhibition of vascular restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and AT-2 antagonist inhibition of vascular restenosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1567889